FARMERS & MERCHANTS TRUST Co OF LONG BEACH Buys Shares of 1,819 Gilead Sciences, Inc. $GILD

FARMERS & MERCHANTS TRUST Co OF LONG BEACH bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,819 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the period. Nuveen LLC bought a new position in Gilead Sciences in the first quarter valued at about $620,415,000. Finally, National Pension Service lifted its holdings in Gilead Sciences by 6.9% in the first quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company’s stock valued at $389,191,000 after acquiring an additional 223,171 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Stock Up 0.5%

Shares of GILD opened at $112.62 on Tuesday. The business’s 50 day moving average is $114.50 and its 200 day moving average is $109.90. The company has a market capitalization of $139.74 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a 12-month low of $82.82 and a 12-month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the sale, the chief executive officer directly owned 595,725 shares in the company, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,000 shares of company stock valued at $8,285,530. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.